trending Market Intelligence /marketintelligence/en/news-insights/trending/TJjLhEtd66qrs8PpwyUJQg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Bristol-Myers Squibb, Calithera enter clinical collaboration for cancer drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Bristol-Myers Squibb, Calithera enter clinical collaboration for cancer drug

Calithera BioSciences Inc. is partnering with Bristol-Myers Squibb Co. to determine whether its CB-839 drug can be combined with Opdivo to treat kidney cancer.

Bristol-Myers' Opdivo is already approved as a treatment for certain types of cancer. CB-839 is currently in phase 1/2 clinical studies involving patients with clear cell renal cell carcinoma.